Stockreport

Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group [Yahoo! Finance]

Lipella Pharmaceuticals Inc.  (LIPO) 
PDF company focused on innovative therapies for serious diseases with significant unmet needs, today announced the completion of dosing for the first cohort in its multi-cen [Read more]